Displaying drugs 7326 - 7350 of 8030 in total
Elismetrep
Elismetrep is under investigation in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects).
Investigational
Matched Description: … in clinical trial NCT02429102 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of …
Davanat
Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).
Investigational
Matched Description: … Davanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil …
VM4-037
VM4-037 is under investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037).
Investigational
Matched Description: … investigation in clinical trial NCT00884520 (An Exploratory, Open Label, Multi-Center, Non-Randomized Study of …
Heparin, bovine
Heparin, bovine is under investigation in clinical trial NCT01072747 (Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass).
Investigational
Matched Description: … Heparin, bovine is under investigation in clinical trial NCT01072747 (Efficacy And Safety Of Unfractionated …
Proxalutamide
Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).
Investigational
Matched Description: … Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide …
Tesnatilimab
Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease).
Investigational
Matched Description: … Tesnatilimab is under investigation in clinical trial NCT04655807 (A Study of JNJ-64304500 as Add-on …
Bexmarilimab
Bexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).
Investigational
Matched Description: … investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of …
Autologous Hematopoietic Peripheral Blood Stem Cells
Autologous hematopoietic peripheral blood stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of refractory myasthenia gravis.
Investigational
Matched Description: … stem cells were tested in a clinical trial (NCT00424489) by Northwestern University for the treatment of …
JNJ-75276617
JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies).
Investigational
Matched Description: … JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination …
CTB001
CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.
Investigational
Matched Description: … 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of …
VCA-894A
VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
Investigational
Matched Description: … VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of …
Tezosentan
Tezosentan is an intravenous endothelin receptor A/B antagonist. Tezosentan was initially developed for vasodilation in patients with acute heart failure but studies have shown that it does not assist in the treatment of dyspnea or prevent cardiovascular events.
Investigational
Matched Description: … in patients with acute heart failure but studies have shown that it does not assist in the treatment of …
Dacetuzumab
Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, Leukemia, Lymphocytic, Chronic, and Lymphoma, Large B-Cell, Diffuse. It is a humanized anti-CD40 antibody and induces cytotoxicity in human multiple myeloma cells.
Investigational
Matched Description: … Dacetuzumab has been used in trials studying the treatment of Multiple Myeloma, Non-Hodgkin Lymphoma, …
GI-101
GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc.
Investigational
Matched Description: … GI-101 is a bi-specific fragment crystallizable region (Fc) fusion protein containing a cluster of differentiation …
Ohmefentanyl
Ohmefentanyl is an extremely potent opioid analgesic drug which selectively binds to the µ-opioid receptor. The Chinese have recorded ohmefentanyl as having a potency that is 6,300 times morphine. Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids such as carfentanil and etorphine which...
Illicit
Matched Description: … Researchers are studying the different pharmaceutical properties of these isomers. ... Ohmefentanyl is one of the most potent μ -receptor agonists known, comparable to super-potent opioids …
LY2140023
LY2140023 is an investigational drug from Lilly, which is being developed as a new treatment option for schizophrenia. LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered, is metabolized to provide the active mGlu2/3 receptor agonist called LY404039. Most currently approved antipsychotic medications...
Investigational
Matched Description: … LY2140023 is an oral "prodrug," meaning it is devoid of intrinsic biological activity and, once administered ... For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of …
Droloxifene
Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell...
Investigational
Matched Description: … Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor ... affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of ... Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because …
CYT006-AngQb
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that...
Investigational
Matched Description: … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. ... It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient …
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Muraglitazar
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Matched Description: … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients ... It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both …
Allogeneic Cardiosphere-Derived Cells
Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and...
Investigational
Matched Description: … their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of ... The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function …
D-Lactic acid
A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
Experimental
Matched Description: … A normal intermediate in the fermentation (oxidation, metabolism) of sugar. …
Daglutril
Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.
Investigational
Matched Description: … mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of …
MLN2222
MLN2222 is a novel, proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of the complement activation pathway.
Investigational
Matched Description: … proprietary recombinant protein that blocks both the C3 and C5 convertases, which are essential components of …
Rivoglitazone
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
Matched Description: … Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes …
Displaying drugs 7326 - 7350 of 8030 in total